Aligos Therapeutics (ALGS) Free Cash Flow (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Free Cash Flow came in at -$23.1 million in Q1 2026, down 10.61% YoY from -$25.9 million in Q1 2025, and down 6.36% on a QoQ basis from -$21.7 million in Q4 2025.
Aligos Therapeutics (ALGS) Free Cash Flow (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Free Cash Flow data on file, last reported at -$23.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 10.61% year-over-year to -$23.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.7 million (down 7.37% YoY) and the FY2025 annual result came in at -$82.5 million, down 2.02% from the prior year.
- Free Cash Flow declined to -$23.1 million in Q1 2026, from -$21.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.6 million in Q2 2023 to a low of -$25.4 million in Q2 2022.
- A 5-year average of -$20.3 million and a median of -$20.9 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 54.32% — and 2024, when it tumbled 43.16%.
- Tracing ALGS's Free Cash Flow over 5 years: stood at -$16.9 million in 2022, then tumbled by 34.28% to -$22.7 million in 2023, then increased by 18.78% to -$18.4 million in 2024, then dropped by 18.16% to -$21.7 million in 2025, then decreased by 6.36% to -$23.1 million in 2026.
- The last three Free Cash Flow figures came in at -$23.1 million (Q1 2026), -$21.7 million (Q4 2025), and -$24.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | -24.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.95 Mn |
| Jun 30, 2026 | -24.95 Mn |
| Mar 31, 2026 | -23.13 Mn |
| Mar 31, 2026 | -23.13 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Sep 30, 2025 | -24.35 Mn |
| Sep 30, 2025 | -24.35 Mn |
| Jun 30, 2025 | -15.50 Mn |
| Jun 30, 2025 | -15.50 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Dec 31, 2024 | -18.40 Mn |
| Dec 31, 2024 | -18.40 Mn |
| Sep 30, 2024 | -20.10 Mn |
| Sep 30, 2024 | -20.10 Mn |
| Jun 30, 2024 | -19.49 Mn |
| Jun 30, 2024 | -19.49 Mn |
| Mar 31, 2024 | -22.75 Mn |
| Mar 31, 2024 | -22.75 Mn |